SCHEMBL2034427

SCHEMBL2034427

CCc1nc(C=O)c(C)n1-c1ccccc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
APLNR P35414 1/20 0.44
HCAR1 Q9BXC0 3/20 0.43
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
MEN1 O00255 3/20 0.36
LMNA P02545 3/20 0.36
KMT2A Q03164 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.36
RBP4 P02753 1/20 0.35
DRD4 P21917 1/20 0.35
GRM2 Q14416 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2031644 0.82 ALDH1A1 (0.45) ALDH1A1L3MBTL1APLNRHCAR1MAPT
SCHEMBL2024924 0.78 ALDH1A1 (0.47) ALDH1A1L3MBTL1APLNRHCAR1MAPT
SCHEMBL2027673 0.75 RBP4 (0.47) ALDH1A1L3MBTL1APLNRHCAR1MAPT
SCHEMBL4559787 0.69 PDE4A (0.47) ALDH1A1L3MBTL1APLNRHCAR1MAPT
SCHEMBL4559786 0.69 L3MBTL1 (0.46) ALDH1A1L3MBTL1APLNRHCAR1MAPT
SCHEMBL25644300 0.68 KDM4E (0.49) ALDH1A1L3MBTL1APLNRHCAR1MAPT
SCHEMBL2031113 0.68 NR3C2 (0.47) ALDH1A1NR1H2NR1H3LMNACYP2C9
SCHEMBL5270064 0.66 KDM4E (0.50) ALDH1A1L3MBTL1HCAR1MAPTKDM4E
SCHEMBL17537377 0.64 MAPT (0.59) ALDH1A1L3MBTL1APLNRHCAR1MAPT
SCHEMBL17931795 0.63 L3MBTL1 (0.51) ALDH1A1L3MBTL1APLNRHCAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844020-B1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS EXELIXIS INC (US) 2017-09-06 EP disclosed
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands EXELIXIS, INC. (US) 2011-06-16 US disclosed
EP-1844020-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS Exelixis, Inc. (US) 2007-10-17 EP disclosed
WO-2007024744-A2 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS EXELIXIS, INC. (US) 2007-03-01 WO disclosed
WO-2006076202-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS EXELIXIS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands NCOA1, NCOA2, NCOA3 ALDH1A1 1665/4885L3MBTL1 4870/4885APLNR 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.